Glenn Sivits
Amgen (United States)(US)
Publications by Year
Research Areas
Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Diabetes Treatment and Management, Fibroblast Growth Factor Research, Epigenetics and DNA Methylation
Most-Cited Works
- → Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice(2008)1,133 cited
- → Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models(2018)219 cited
- → Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue(2015)194 cited
- → Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism(2020)131 cited
- → Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia(2009)106 cited
- → Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors(2013)97 cited
- → Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor(2010)55 cited
- → Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 3. Structure–Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N′-arylpiperazine Series(2014)52 cited
- → Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N → S (nN → σ*S–X) Interaction for Conformational Constraint(2015)40 cited
- → Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept(2014)33 cited